These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 17159912)

  • 21. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
    Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
    Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of polyanhydride chemistry in particle-based cancer vaccines on the magnitude of the anti-tumor immune response.
    Wafa EI; Geary SM; Goodman JT; Narasimhan B; Salem AK
    Acta Biomater; 2017 Mar; 50():417-427. PubMed ID: 28063991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CpG immunostimulatory sequences enhance contact hypersensitivity responses in mice.
    Akiba H; Satoh M; Iwatsuki K; Kaiserlian D; Nicolas JF; Kaneko F
    J Invest Dermatol; 2004 Sep; 123(3):488-93. PubMed ID: 15304088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytidine-phosphate-guanosine oligodeoxynucleotides and interferon-alpha-expressing tumor cells effectively induce dendritic cell maturation in vitro.
    Hiraide A; Hiroishi K; Ishii S; Eguchi J; Imawari M
    Anticancer Res; 2006; 26(1A):211-8. PubMed ID: 16475701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antennapedia transduction sequence promotes anti tumour immunity to epicutaneously administered CTL epitopes.
    Schutze-Redelmeier MP; Kong S; Bally MB; Dutz JP
    Vaccine; 2004 May; 22(15-16):1985-91. PubMed ID: 15121311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fusion of CpG-ODN-stimulating dendritic cells with Lewis lung cancer cells can enhance anti-tumor immune responses.
    Du YC; Lin P; Zhang J; Lu YR; Ning QZ; Wang Q
    Tissue Antigens; 2006 May; 67(5):368-76. PubMed ID: 16671943
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COX-2 inhibition enhances the TH2 immune response to epicutaneous sensitization.
    Laouini D; Elkhal A; Yalcindag A; Kawamoto S; Oettgen H; Geha RS
    J Allergy Clin Immunol; 2005 Aug; 116(2):390-6. PubMed ID: 16083795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles.
    Zhang XQ; Dahle CE; Baman NK; Rich N; Weiner GJ; Salem AK
    J Immunother; 2007; 30(5):469-78. PubMed ID: 17589287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides.
    Baines J; Celis E
    Clin Cancer Res; 2003 Jul; 9(7):2693-700. PubMed ID: 12855649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Self-assembling CpG DNA nanoparticles for efficient antigen delivery and immunostimulation.
    Rattanakiat S; Nishikawa M; Takakura Y
    Eur J Pharm Sci; 2012 Sep; 47(2):352-8. PubMed ID: 22771546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection.
    Tewary P; Pandya J; Mehta J; Sukumaran B; Madhubala R
    FEMS Immunol Med Microbiol; 2004 Oct; 42(2):241-8. PubMed ID: 15364110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of oral administration of CpG ODN-OVA on WBB6F1-W/Wv mice.
    Teshima R; Okunuki H; Sato Y; Akiyama H; Maitani T; Sawada J
    Allergol Int; 2006 Mar; 55(1):43-8. PubMed ID: 17075285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant.
    Jérôme V; Graser A; Müller R; Kontermann RE; Konur A
    J Immunother; 2006; 29(3):294-305. PubMed ID: 16699372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.
    Tewary P; Sukumaran B; Saxena S; Madhubala R
    Vaccine; 2004 Aug; 22(23-24):3053-60. PubMed ID: 15297055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CpG oligodeoxynucleotides potentiate the antitumor activity of anti-BST2 antibody.
    Hiramatsu K; Serada S; Kobiyama K; Nakagawa S; Morimoto A; Matsuzaki S; Ueda Y; Fujimoto M; Yoshino K; Ishii KJ; Enomoto T; Kimura T; Naka T
    Cancer Sci; 2015 Oct; 106(10):1474-8. PubMed ID: 26498112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccinations with T-helper type 1 directing adjuvants have different suppressive effects on the development of allergen-induced T-helper type 2 responses.
    Trujillo-Vargas CM; Mayer KD; Bickert T; Palmetshofer A; Grunewald S; Ramirez-Pineda JR; Polte T; Hansen G; Wohlleben G; Erb KJ
    Clin Exp Allergy; 2005 Aug; 35(8):1003-13. PubMed ID: 16120081
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Local therapy with CpG motifs in a murine model of allergic airway inflammation in IFN-beta knock-out mice.
    Matheu V; Treschow A; Teige I; Navikas V; Issazadeh-Navikas S
    Respir Res; 2005 Mar; 6(1):25. PubMed ID: 15748290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice.
    Zeytin HE; Patel AC; Rogers CJ; Canter D; Hursting SD; Schlom J; Greiner JW
    Cancer Res; 2004 May; 64(10):3668-78. PubMed ID: 15150127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer.
    Lubaroff DM; Karan D; Andrews MP; Acosta A; Abouassaly C; Sharma M; Krieg AM
    Vaccine; 2006 Aug; 24(35-36):6155-62. PubMed ID: 16876291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-4 and CpG oligonucleotide therapy suppresses the outgrowth of tumors by activating tumor-specific Th1-type immune responses.
    Kajiwara A; Doi H; Eguchi J; Ishii S; Hiraide-Sasagawa A; Sakaki M; Omori R; Hiroishi K; Imawari M
    Oncol Rep; 2012 Jun; 27(6):1765-71. PubMed ID: 22426807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.